Carbohydrate antigen 19-9 as a serum marker of hepatocellular carcinoma: Comparison with alpha-foetoprotein

Kew, Michael C.; Berger, Evelyn; Koprowski, Hilary

doi:10.1038/bjc.1987.160

Cited by 17 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the CA19-9 assay was originally developed to detect patients with colorectal adenocarcinoma (Koprowski et al, 1981), subsequent work revealed that the serum levels of this antigen were raised in a greater proportion of patients with pancreatic and hepatobiliary malignancies than those with large bowel cancer (Ritts et al, 1984;Kew et al, 1987). The oesophagus, like the pancreas and the liver, is a foregut derivative and this study was undertaken in the hope that CA19-9 might prove a useful tumour marker for oesophageal carcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer

McKNIGHT

Mannell²,

Shperling³

1989

Br J Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Excessive quantities of this antigen have been found in patients with gastrointestinal malignancies, including colorectal, pancreatic and hepatocellular carcinomas (Ritts et al, 1984;Kew et al, 1987). The oesophagus, like the pancreas and liver, is a foregut derivative and it is possible that oesophageal carcinoma may also express this antigen.…”

mentioning

confidence: 99%

The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer

McKNIGHT

Mannell²,

Shperling³

1989

Br J Cancer

View full text Add to dashboard Cite

“…It is a quite accurate indicator of HCC and correlates to tumor size, but it is not sensitive enough to detect early small HCC [18,19]. Also molecules such as ferritin, carbohydrate antigen 19-9, immune complexes and monoclonal antibodies are no improvement on the simple AFP assay [20][21][22][23]. PAP is a protein of pancreatic origin [8] but is also produced by intestinal cells [24] and its gene is activated in the liver during carcinogenesis [10,11].…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of Pancreatitis-Associated Protein as a Serum Marker of Hepatocellular Carcinoma: Comparison with α-Fetoprotein

Montalto

Iovanna²,

Soresi³

et al. 1998

Oncology

View full text Add to dashboard Cite

This study evaluated the significance of serum pancreatitis-associated protein (PAP) assay, as a marker of hepatocellular carcinoma (HCC), in comparison and combined with α-fetoprotein (AFP) assay. Sixty-five patients with HCC, 59 with liver cirrhosis (LC) and 68 asymptomatic controls (C) were studied. PAP and AFP values significantly increased from C to LC and HCC group (p < 0.0001). The area under receiver-operating characteristic (ROC) curve for the two markers was not statistically different. At 100% specificity, ROC analysis gave a cut-off level for AFP of 166 IU/l with 40% sensitivity, and a cut-off level of 240 µg/l for PAP with 23% sensitivity. Diagnostic accuracy of combined AFP and PAP assay was significantly higher than AFP alone. Sensitivity according to tumor size also improved using the combined assay, especially for tumors <5 cm. Stepwise logistic regression indicated that AFP, but not PAP, was associated with an increased risk of developing HCC. These data confirm that PAP production is increased only in some cases of HCC and that the combined PAP and AFP assays do not significantly improve specificity over AFP assay alone. Consequently, PAP assay can only be recommended in cases of justified suspicion of HCC with negative AFP.

show abstract

“…In patients with hepatocellular car cinoma (HCC), the serum CEA as well as CA19-9 may be elevated in some instances. However, the levels are usually mild to moderate (4)(5)(6)(7)(8). We describe a case of HCC with extremely high serum CEA and CA19-9 levels, which ultimately reached 26,800 ng/ml and 5,500 U/ml, respectively.…”

Section: Introductionmentioning

confidence: 99%

“…Using monoclonal anti-CEA antibody, we have firstly verified CEA which is produced by HCC cells. CA19-9 is regarded to be less useful as a tumor marker than alpha-fetoprotein in cases of HCC (7,8). Serum CA19-9 titer in patients with HCC has been reported to increase at most three-to four-fold (8) above the normal level.…”

Section: Internalmentioning

confidence: 99%